We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
BlueJay are a social radio which allow the user to create their very own livestream playlist which they can share with a small group of friends or thousands of followers. BlueJay is a free music app available on Android and IOS and allows users to share their own music or follow their favourite artists or friends to discover new music. 
days to go: Expired investment: £153,788
Quin is a mobile medical app that combines daily life experience with data from diabetes devices and phones and helps people decide how much insulin to take and when. They are on a mission to help people with insulin-treated diabetes make the best possible decisions through their app. The company have received a UK research and innovation grant. Apple has granted them insider access to their engineers and executives who are helping to get Quin to market, their app has a class I CE Mark, with two patents pending. With the investment, they will hire a product designer to enhance the user experience, achieve certification and compliance with new European Medical Device Regulations, develope B2B2C distribution partnerships and launch the Quin app in the UK and Europe in late 2020.

Pitch Rated

48%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £691,497
FreeHand is a robotic surgical camera controller that aims to make surgeries precise and safer. The company cites data arguing that over 15 million keyhole surgeries are performed annually in which an additional clinician is mostly required to manually hold the camera the surgeon uses to see the operating field. The company asserts that this is not the most optimal way. FreeHand's robotic camera controller aims to solve this issue by providing steady images and precise control, saving time, and improving outcomes. The company has regulatory clearance for sale in the EU, US, and Japan. FreeHand points out that surgical robotics is one of the fastest-growing segments in Medical Technology, projected to reach $91.5 billion by 2025. It aims to become a contender in this segment. FreeHand claims that surgeons have successfully used its robotic controller in more than 15,000 procedures. The company will use the investment to expand the distributor base in Europe, Asia and Latin America, targeting over 12 million procedures annually.
days to go: Expired investment: £1,003,350
A medical condition management platform allowing clinicians to create their own app to improve a patient's health whilst reducing costs. Living With develops smart apps specific to a person's condition, they currently have 3 products with another in the development stage. Their primary app, Squeezy, is the top paid medical app in the UK that helps patients with their pelvic floor exercises. Other apps, allow clinicians to monitor a patient's bowel and bladder health, as well as those with rheumatoid arthritis. These apps are already in use at multiple NHS Trusts and clinics. Funds are being raised to complete development of their apps to help those with lupus and lung cancer, in addition to further developing their existing products. The company aims to have thousands of apps that will be available worldwide to provide self-service treatment at any time. Living With is expecting to earn £1.07m in revenue by the end of March 2019.
days to go: Expired investment: £250,000
Podcast Radio (PR) is the Ofcom-licensed UK digital broadcast radio station showcasing podcasts 24/7 globally. It is currently broadcasting in Surrey, Manchester, London, and Glasgow. Podcasting is expected to become a $3.3 billion industry by 2025. PR aims to be a disruptor in this segment. PR got front-page coverage in the international edition of Radio World magazine and has onboarded US radio Disc Jockey (DJ) Gene Baxter. The company will use 15% of the investment to secure digital radio broadcast transmission in 5 more UK cities by the end of 2020, 15% to partner with applicants for new digital radio transmitters, 15% to create a PR-led UK marketing campaign supported by social media, 25% to recruit new staff members, 10% to develop its on-air content, 10% to develop its website and application, and 10% to build new business partnerships to drive the international expansion of the company.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £149,023
The story of Laurie Cunningham, the first black footballer to play for England
days to go: Expired investment: £80
DMD has made its digital content distribution enterprise in the last two years. Along with that, it has developed a global cinema TVOD (Transactional Video On Demand product). The company has built a long-term distribution partnership with OTT companies, telephone/IPTV and major cable that lead the wealthiest portion of the Pay TV market, providing service to 17 million two-way homes in 19 nations in Latin America. DMD's revenue has increased by 93% YoY 2017-2018, which will help the company in reaching EBITDA breakeven in Q3 of 2019. DMD has established relationships with distributors and leading sales agents in Europe and the USA. With the proceeds, the company will acquire bigger commercial films, increase its global footprint by launching the company in Asia, Africa, and Europe, and supplement its current output with classic titles.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £145,000
Cell Guidance Systems is developing a technology called PODS (Polyhedrin Delivery System) PODS allow them to deliver therapeutic proteins accurately and over long periods of time. PODS enable proteins to treat diseases, such as Parkinson’s disease and osteoarthritis.
days to go: Expired investment: £836,370
Luas Diagnostics (LD) aims to develop and market easy-to-use, rapid and accurate diagnostics tests with the aim of deploying these tests in remote settings away from centralised testing laboratories. The company has signed an exclusive distribution agreement with Chembio Diagnostics Systems (CDS) in the USA to market its Covid-19 antibody and antigen tests in the UK and Ireland. It has also signed a Memorandum of Understanding (MoU) with the University of Birmingham to develop saliva-based, rapid Covid-19 tests. LD is also working on coming up with a therapeutic drug monitoring system based on the same technology used worldwide to test people with diabetes for glucose levels in the blood. The company is developing the system so that it can be used at home, in pharmacies or GP surgery. The first product will test for Theophylline which is used to treat Chronic Obstructive Pulmonary Disease (COPD). LD will use the investment to grow its business across different verticals.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £326,190
Arcis Biotechnology provide nucleic acid sample preparation solutions. They have made the process of obtaining genetic material from biological samples less time consuming so it can be done in less than 3 minutes.
days to go: Expired investment: £1,146,318
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph